Ectopic endometrial cell

Ectopic endometrial cells are the primary pathological component of endometriosis, a chronic condition where tissue similar to the uterine lining grows outside the uterine cavity, typically on pelvic organs (StatPearls, 2023). These cells exhibit abnormal biological behaviors compared to eutopic endometrial cells, including increased resistance to apoptosis, enhanced invasive capacity, and heightened production of inflammatory cytokines and prostaglandins (Nature Reviews Disease Primers, 2018). They are highly sensitive to ovarian steroids, particularly estrogen, which drives their proliferation, survival, and the cyclic bleeding that leads to inflammation (NIH, 2023). Therapeutic strategies targeting these cells often focus on inducing a hypoestrogenic environment to starve the lesions of their primary growth stimulus or using progestins to induce decidualization and subsequent atrophy (Mayo Clinic, 2023). Common pharmacological interventions include GnRH receptor antagonists like elagolix and agonists like leuprorelin, which suppress the hormonal axis supporting these cells (PubMed, 2021). Additionally, progestins like dienogest act directly on these cells to inhibit their growth and reduce the associated inflammatory response (StatPearls, 2023). While not a single molecular target, these cells represent the functional unit that drugs aim to eliminate or suppress to alleviate the chronic pain and infertility associated with the disease.

Other names

Endometriotic cellEctopic endometriumEndometriotic lesionEndometriosis-associated cell

Suppression of the hypothalamic-pituitary-gonadal axis to induce a hypoestrogenic state, direct inhibition of cell proliferation, and reduction of inflammation.